11th Annual Oncology Innovation Forum

7 Hills Pharma is a clinical-stage immunotherapy company advancing novel drugs for the treatment of advanced cancers. Our molecules are designed with a unique combination of high efficacy and low toxicity, and they leverage a new mechanism of action fundamental to combating tumor immune evasion. Alintegimod is the first clinical-stage molecule to emerge from 7 Hills Pharma’s proprietary platform of integrin agonists. Alintegimod is a first-in-class, oral small molecule designed to improve the effectiveness of immune checkpoint inhibitors against treatment-resistant solid tumors without adding toxicity. Alintegimod uniquely activates integrins, cell adhesion molecules critical to generating an effective anti-tumor immune response, including T cell activation and tumor infiltration. Alintegimod is undergoing a Phase Ib/IIa clinical trial, in combination with dual immune checkpoint blockade, in patients with aPD-1-resistant solid tumors. A major data readout is planned for 1Q2026. With a financial runway through 2026, the company is pre-marketing a $25MM Series A round, aimed to close in 2H2026, to establish alintegimod clinical proof-of-concept and deliver investor returns within three years via out-licensing. We are also raising up to $4MM in angel/family office funds via a convertible note offering favorable terms and designed to convert into the Series A raise.

Cullinan Therapeutics, Inc. is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients.

Toray Industries, Inc. founded in 1926, is a global chemical company and a leader in cutting-edge, high value-added products including fibers, textiles, plastic resins, fine chemicals, films, carbon fiber composite materials, electronics and information-related products, pharmaceutical and medical products, and products for the water treatment and environmental fields. While the pharmaceutical and medical products sector currently represents a relatively small share of our overall business, we are placing strong emphasis on the development of innovative cancer therapeutics. To achieve this, we have established original technology for discovering novel cancer targets. Leveraging this platform, we have successfully discovered promising novel targets and advanced the development of cutting-edge cancer therapeutics directed at these targets.

Creating the ideal immunotherapy for solid tumors which provides potent tumour-selective delivery and tumour-selective killing ability through IV delivery. Lead program entering the clinic in 2025.

We are an emerging biotechnology company tackling the fundamental issue that causes the immune system to malfunction. We do this using a naturally occurring active enzyme, what we call a “Rescue Protein” to rebalance the immune system. We are differentiated from the competitive landscape in the following manner, the novel Rescue Proteins we use enable us to activate cytokine receptor pathways for up to 5 days following a 1 hour incubation with the protein, eliminating the toxicities associated with systemic IL-2 administration; the cells treated with Rescue Proteins are administered to intact individuals without any preconditioning; we have seen meaningful clinical effects using doses of 106 cells/kg; the use of a protein based approach only requires a 1 hour incubation of target cells ex vivo, therefore shortening the production time to hours rather than days; we are using a Rescue Protein with a well defined mechanism of action that is also susceptible to inhibition by a drug that has been approved and in the clinic for many years, providing a naturally built in safety switch. We aim to begin dosing patients in a first in human clinical trial evaluating the safety and tolerability, dose escalation and early efficacy of our novel cell based immunotherapy on adenocarcinoma patients who have either relapsed or become refractory and have run out of therapeutic options. This clinical trial will begin dosing patients in Q1 2026. We’ve proven this approach with Tat-MYC in clinical trials, including conditional approval in Japan. However, we appreciate the challenges with Tat-MYC and have chosen a different rescue protein. We are happy to share preclinical data when we talk and can share the target under CDA. We and our advisor would welcome the chance to review the company with you, including our current financing round.

BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform. Biomunex is developing a disruptive biological approach, the MAIT-engagers, that redirect MAIT cells to kill cancer cells, which may become a true game changer in the field of cancer immunotherapy.

Biond Biologics – Advancing First-in-Class Immunotherapies Biond Biologics is a private, clinical-stage biotechnology company developing a pipeline of first-in-class immunotherapies for cancer and immune-related diseases. Our programs target novel pathways across both innate and adaptive immunity, supported by deep translational science and biomarker-driven clinical development.

Laverock Therapeutics is powering the development of disease-responsive advanced therapies through our unique, programmable gene control technology. Our innovative platform harnesses the cell’s natural regulatory mechanisms to deliver programmable and tunable gene control through recoded miRNAs. This enables the development of highly effective medicines with enhanced precision and improved safety profiles. Utilising our platform technologies, we are working to develop the next-generation of advanced therapies, both through our own pipeline – targeting oncology and genetic medicine – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock has raised more than £20m seed funding to date from high-calibre investors including Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos Advisory, UK Innovation & Science Seed Fund, Tekfen Ventures and Norcliffe Capital.

NEOK Bio is a therapeutics company developing novel bispecific antibody drug conjugates (ADCs) to improve outcomes for cancer patients.

OxSonics is a game changing MedTech company, spun out from the University of Oxford, a Focused Ultrasound Center of Excellence. The company has developed a novel, breakthrough ultrasound-mediated drug delivery platform to significantly improve delivery of anti-cancer drugs into the target tumor site. Located in Oxford, the team is made of 7 people whose 50% are PhD. SonoTran® is a platform comprising a proprietary ultrasound engine and Sonosensitive Particles which are co-administered and systemically infused alongside anti-cancer drugs. OxSonics has recached a major inflection point with the completed In first‑in‑human mCRC trial , SonoTran® improved response rates (86% vs 67%), with complete responses in 4/7 patients without any device-related safety issues reported.

In 2021, Vitarka Therapeutics was founded with the aim of solving the endosomal entrapment problem by developing the EndoPore platform for cytosolic delivery of potent therapeutics against intracellular targets. Currently, only 20% of cancer targets are druggable, leaving 80% undruggable. Vitarka's EndoPore technology addresses this by providing highly efficient and selective two-stage tumour targeting with safe and effective cytosolic release of potent degrader payloads.